Psych Capital Plc
A life sciences firm developing psilocybin treatments for anorexia and mental health conditions.
PSY | IL
Overview
Corporate Details
- ISIN(s):
- GB00BL6CJQ54
- LEI:
- 213800WXCQ1C6GPLHH68
- Country:
- United Kingdom
- Address:
- 17 HANOVER SQUARE, W1S 1BN LONDON
- Website:
- https://psych.capital/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Shortwave Life Sciences Plc, formerly Psych Capital Plc, is a life sciences company focused on developing innovative treatments for mental health conditions. The company has transitioned from its prior role as an investment and media firm to a dedicated drug development entity following its acquisition of Short Wave Pharma. Its primary clinical program focuses on advancing psilocybin as a potential breakthrough therapy for anorexia nervosa, a condition with no FDA-approved medication. Rooted in the Israeli innovation ecosystem, Shortwave employs an IP-driven, capital-efficient strategy, utilizing strategic partnerships to optimize its drug discovery and development processes for eating disorders and other mental health indications.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-06 08:25 |
Regulatory News Service
Patent Application Publication
|
English | 13.4 KB | ||
| 2025-11-04 12:45 |
Pre-Annual General Meeting Information
AGM, Treasury Policy & Capital Reorganisation
|
English | 44.0 KB | ||
| 2025-10-31 16:25 |
Annual Report
ANNUAL REPORT AND ACCOUNTS TO 30 APRIL 2025
|
English | 248.8 KB | ||
| 2025-09-10 08:00 |
Board/Management Information
Direction, Director Changes and Medical Adviser
|
English | 20.9 KB | ||
| 2025-08-19 13:50 |
Major Shareholding Notification
Holding(s) in Company
|
English | 56.0 KB | ||
| 2025-08-04 12:00 |
Board/Management Information
Clarification on Strategic Advisor Appointment
|
English | 6.0 KB | ||
| 2025-07-29 08:00 |
Share Issue/Capital Change
£250k Fundraising, New Directors & Review
|
English | 27.3 KB | ||
| 2025-06-24 14:10 |
Major Shareholding Notification
AQSE Only - Holding(s) in Company
|
English | 56.2 KB | ||
| 2025-06-16 11:21 |
Major Shareholding Notification
Holding(s) in Company
|
English | 56.2 KB | ||
| 2025-01-31 17:52 |
Earnings Release
Interim Results to 31 October 2024
|
English | 115.6 KB | ||
| 2024-12-23 13:00 |
Share Issue/Capital Change
Pre-Crowdfunding re Groundbreaking Treatment
|
English | 9.5 KB | ||
| 2024-11-29 16:16 |
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
|
English | 7.2 KB | ||
| 2024-11-27 15:12 |
Board/Management Information
Director Appointment and SPA Update
|
English | 26.7 KB | ||
| 2024-10-31 18:39 |
Annual Report
YEAR ENDED 30 APRIL 2024 AND DIRECTOR RESIGNATION
|
English | 176.8 KB | ||
| 2024-09-19 08:00 |
Regulatory News Service
Positive Pre-Clinical Result Drive to Human Trials
|
English | 10.7 KB |
Automate Your Workflow. Get a real-time feed of all Psych Capital Plc filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Psych Capital Plc
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Psych Capital Plc via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
